SHOPLINE, the Commerce SaaS and Solution Provider, Teams Up with Tessera to Revolutionize Customer Experience and Elevate Brand Impact Across Asia
TAIPEI, Jan. 7, 2025 /PRNewswire/ -- As the future of retail shifts towards an integrated omnichannel ecosystem, it is projected to become a trillion-dollar industry. While many businesses already possess strong products and distribution channels,...
Yaber at CES 2025: Color the Movie Night
Enjoy Stunning Visuals with Yaber's Powerful K300s, L2 Plus, and T2 Series LAS VEGAS, Jan. 7, 2025 /PRNewswire/ -- Yaber, a pioneer in entertainment projectors, introduces three groundbreaking models: the ultra-short throw laser projector K300s, the...
The Registrational Clinical Data of Glecirasib was Published in Nature Medicine
BEIJING, SHANGHAI and BOSTON, Jan. 7, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed...
Amazfit Announces the Active 2; the Ultimate Everyday Smartwatch for Active and Healthy Living
MILPITAS, Calif., Jan. 7, 2025 /PRNewswire/ -- Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, today announced the launch of its latest lifestyle smartwatch: the Amazfit Active 2, a...
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](http://prnewswire.vietreader.com/thumb/190x300/2025-01/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-eflornithine-difluoromethylornithine-dfmo-in-high-risk-neuroblastoma-1.jpg)
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releases Next media release LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma...
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
SHANGHAI and SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therapeutics, Inc....
LG UNVEILS A DAY IN A LIFE WITH "AFFECTIONATE INTELLIGENCE" AT LG WORLD PREMIERE
Company Showcases Future of AI-Powered Customer Experiences Through CEO Keynote and Immersive Storytelling LAS VEGAS, Jan. 7, 2025 /PRNewswire/ -- LG Electronics (LG) unveiled its vision for AI-powered customer experiences themed "Life's Good 24/7...
Blue Owl Capital Hires Algebris Investments' Yoichi Nakamura to Lead Private Wealth in Japan
Yoichi brings over two decades of experience covering securities companies and scaling the wealth businesses for global asset managers within the Japanese market NEW YORK and TOKYO, Jan. 7, 2025 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl")...